Janssens R, Lang T, Vallejo A, Galinsky J, Morgan K, Plate A, De Ronne C, Verschueren M, Schoefs E, Vanhellemont A, Delforge M, Schjesvold F, Cabezudo E, Vandebroek M, Stevens H, Simoens S, Huys I. What matters most to patients with multiple myeloma? a Pan-European patient preference study. Front Oncol. 2022 Nov 29;12:1027353. doi: 10.3389/fonc.2022.1027353
Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Montserrat-Capdevila J, Godoy P, Marsal JR, Ortega M, Pifarre J, Alseda P, Castan MT, Barbe F. Mental disorders in chronic obstructive pulmonary diseases. Perspect Psychiatr Care. 2018 Jul;54(3):398-404. doi: 10.1111/ppc.12274
Pinto MD, Greenblatt AM, Hickman RL, Rice HM, Thomas TL, Clochesy JM. Assessing the critical parameters of eSMART-MH: a promising avatar-based digital therapeutic intervention to reduce depressive symptoms. Perspect Psychiatr Care. 2016 Jul;52(3):157-68. doi: 10.1111/ppc.12112
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603